Farallon Capital Management
http://www.faralloncapital.com/farallon/index.htmFarallon Capital Management is an investment firm than manages equity capital for institutions and high net worth individuals. The firm's institutional investors are primarily college endowments and foundations. Farallon primarily invests in businesses and securities that are undergoing change or will appreciate because of an expected event which includes mergers, restructurings, recapitalizations or other major changes. The firm seeks to build strong relationships with the management of companies in which it invests.
View Older Stories View More Recent Stories
-
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A NEW YORK TIMES CO Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Elevation Oncology, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Lantheus Holdings, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A AGIOS PHARMACEUTICALS, Filed by: Farallon Capital Partners, L.P.
-
KKR sweetens offer for Fuji Soft as bidding war with Bain goes another round
-
Tectonic Therapeutic (TECX) Announces $185M Private Placement
-
Tectonic Announces $185 Million Private Placement
-
KKR extends tender offer period for Japan's Fuji Soft to Jan 9
-
Bain and KKR battle for Fuji Soft heats up as Bain goes hostile
-
Fuji Soft rejects Bain's raised buyout offer and sticks with KKR
-
Nasdaq Private Market Announces 2024 Executive Leadership Team Promotions
-
Explainer-What's behind the private equity battle for Fuji Soft?
-
Form SC 13G Lantheus Holdings, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-NT Farallon Capital Europe For: Sep 30
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Sep 30
-
Form SC 13G/A Longboard Pharmaceutical Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Aramark Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A AGIOS PHARMACEUTICALS, Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Elevation Oncology, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Beam Therapeutics Inc. Filed by: Farallon Capital Partners, L.P.
-
NexPoint Raises Concerns About UDF IV Board Allowing Millions in Management Fees to Enrich Former UDF Executives Imprisoned for Fraud
-
Form SC 13G/A Savara Inc Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Swiftmerge Acquisition Filed by: Farallon Capital Partners, L.P.
-
KKR acquires 35% of Fuji Soft after first stage of tender offer
-
Fuji Soft's top shareholder confirms support for KKR takeover bid
-
KKR extends tender period for Fuji Soft to November
-
Fuji Soft board backs first stage of KKR's buyout offer
-
Fuji Soft founder backs buyout by Bain over KKR offer, letter says
-
Form SC 13D Squarespace, Inc. Filed by: Farallon Capital Partners, L.P.
-
eGenesis Raises $191 Million Series D Financing to Advance Lead Program for Kidney Transplant
-
Form N-PX FARALLON CAPITAL MANAGEM For: Jun 30
-
Newmark Secures $985 Million Financing on Behalf of 80 Clarkson Developers in New York City
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
-
Form 13F-NT Farallon Capital Europe For: Jun 30
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Jun 30
-
Anaptysbio (ANAB) Prices 2.75M Share Offering at $36.50/sh
-
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
-
Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases
-
CASI Pharmaceuticals (CASI) announces appointment of Daniel Lang, MD as CFO and SVP
-
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP
-
Form D/A Farallon Capital F5 Inve
-
Form D/A Farallon Capital F5 Inve
-
Savara (SVRA) Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
-
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
-
Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
-
Form SC 13G NanoString Technologies Filed by: Farallon Capital Partners, L.P.

